Collaborative Medicinal Development, LLC Reports that Lead Drug Modifies ALS Progression

MILL VALLEY, Calif., Jan. 7, 2019 /PRNewswire/ -- Collaborative Medicinal Development LLC ("CMD"), a privately-held biopharmaceutical company developing innovative therapies for neurodegenerative diseases, reported promising results from its phase 1 dose-finding study of CuATSM for treatment of ALS at the 29^th International Symposium on ALS/MND held in Glasgow, Scotland from December 7-9, 2018. In a presentation, Dr. Craig Rosenfeld, CMD's CEO, reported that over 24 weeks treatment at the recommended phase 2 dose, evaluable patients with sporadic ALS showed a dramatic slowing in disease progression by ALSFRS-R score (-0.29 points/month compared with an expected -1.02 points/month), an improvement in respiratory function by FVC (+1.1 % predicted/month compared with an expected -2.24 % predicted/month), and improvement in cognitive function by ECAS score (+10 points over 24 weeks compared with no change expected).  At lower CuATSM dose levels, evaluable patients showed expected decreases in ALSFRS-R score and FVC over 24 weeks, providing a dramatic dose-response effect previously observed in ALS mouse models.  CMD plans to initiate a randomized, placebo-controlled study of CuATSM in ALS to confirm the promising results seen in the open-label phase 1 study.

About Collaborative Medicinal Development
CMD is a privately-held biopharmaceutical company developing innovative therapies for neurodegenerative diseases.  The Company's lead drug, CuATSM, was licensed from the University of Melbourne and entered clinical trials in ALS and Parkinson's disease in 2017 at leading clinical centers in Australia. The CMD team includes Craig Rosenfeld, MD (CEO), Kay Noel, PhD (COO), Ashley Bush, MD, PhD (CSO), and Jim Babcock (Chairman, founder of Cthulhu Ventures LLC, CMD's founding investor). 

About Amyotrophic Lateral Sclerosis (ALS)
ALS is a progressive and fatal neurodegenerative disease characterized by muscle weakness resulting from degeneration of motor neurons. Patients usually die of respiratory failure within 2 to 3 years of symptoms onset.  There is an urgent unmet medical need for disease modifying therapies in ALS.  Further information about ALS is available at

Contact Information
For further Information
Rory Hill, Business Development
     

View original content to download multimedia:

SOURCE Collaborative Medicinal Development, LLC